A Safety and Efficacy Study of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Moderately Emetogenic Chemotherapy - Full Text View

Purpose

This is a Phase 3, multicenter, randomized, parallel-group, double-blind, active-controlled study of rolapitant in subjects receiving MEC. Rolapitant or placebo will be administered prior to the initiation of chemotherapy on Day 1 with granisetron and dexamethasone. Subjects will record all events of emesis and the use of rescue medication for established nausea and/or vomiting, and will indicate the severity of nausea they experienced in each of the previous 24 hours in the Nausea and Vomiting (NV) Subject Diary prior to the MEC administration through Day 6 in Cycle 1. Health-related quality of life will be measured by the FLIE Questionnaire on Day 6 of Cycle 1. Safety and tolerability will be assessed by clinical review of adverse events (AEs), physical examination, electrocardiograms (ECGs), and safety laboratory values. All subjects are expected to complete Cycle 1 and will have the option of participating in up to five additional cycles.

Condition	Intervention	Phase
Chemotherapy-induced Nausea and Vomiting	Drug: Rolapitant Drug: Granisetron Drug: Dexamethasone	Phase 3

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Prevention
Official Title:	A Phase 3, Multicenter, Randomized, Double Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Moderately Emetogenic Chemotherapy

Resource links provided by NLM:

MedlinePlus related topics: Nausea and Vomiting

Drug Information available for: Dexamethasone Dexamethasone acetate Dexamethasone sodium phosphate Granisetron hydrochloride Granisetron

U.S. FDA Resources

Further study details as provided by Tesaro, Inc.:

Primary Outcome Measures:

No Emetic Episodes and No Rescue Medication [ Time Frame: >24 to 120 hours post chemotherapy ] [ Designated as safety issue: No ]
The primary objective of this study is to determine whether administration of rolapitant with granisetron and dexamethasone improves CINV in the delayed phase (>24 to 120 hours) of CINV compared with administration of placebo with granisetron and dexamethasone in subjects receiving MEC. The primary outcome will be based on complete response (defined as no emetic episodes and no rescue medication) in the delayed phase (>24 to 120 hours).

Secondary Outcome Measures:

Acute Phase Response [ Time Frame: 0 to 24 hours ] [ Designated as safety issue: No ]
To determine the effect of rolapitant on complete response rates in the acute (0 to 24 hours) phase of CINV.
Overall Response Rate [ Time Frame: 0 to 120 hours ] [ Designated as safety issue: No ]
To determine the effect of rolapitant on complete response rate in the overall (0 to 120 hours) phase of CINV.
Safety and Tolerability [ Time Frame: 30 days post study drug ] [ Designated as safety issue: No ]
To evaluate the safety and tolerability of rolapitant in subjects receiving HEC as assessed by the incidence and severity of AEs.

Estimated Enrollment:	1350
Study Start Date:	February 2012
Estimated Study Completion Date:	June 2013
Estimated Primary Completion Date:	December 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Placebo Comparator: Placebo + Granisetron + Dexamethasone Day 1: Placebo + Granisetron (2 mg PO)+ Dexamethasone (20 mg PO) Days 2-3: Granisetron (2 mg PO) will be administered orally.	Drug: Granisetron 2 mg PO Drug: Dexamethasone 20 mg PO
Experimental: Rolapitant Day 1: Rolapitant (200 mg PO) + Granisetron (2 mg PO)+ Dexamethasone (20 mg PO) Days 2-3: Granisetron (2 mg PO) will be administered orally.	Drug: Rolapitant 200 mg PO Drug: Granisetron 2 mg PO Drug: Dexamethasone 20 mg PO

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

18 years of age or older, of either gender, and of any race
Naïve to moderately or highly emetogenic chemotherapy, and is to receive a first course of MEC including one or more of the following agents: cyclophosphamide IV (<1500 mg/m2), doxorubicin, epirubicin, carboplatin, idarubicin, ifosfamide, irinotecan, daunorubicin, cytarabine IV (>1 g/m2).
Karnofsky performance score of ≥60
Predicted life expectancy of ≥4 months
Adequate bone marrow, kidney, and liver function

Exclusion Criteria:

Contraindication to the administration of prescribed MEC agent,granisetron, or dexamethasone
Is pregnant or breast feeding
Has taken the following agents within the last 48 hours 5-HT3 antagonists,Phenothiazines,Benzamides,Domperidone,Cannabinoids,NK1 antagonist, Benzodiazepines
Scheduled to receive any other chemotherapeutic agent with an emetogenicity level of 3 or above (Hesketh Scale) from Day -2 through Day 6, except on Day 1
Scheduled to receive any radiation therapy to the abdomen or pelvis from Day -5 through Day 6
Has received systemic corticosteroids or sedative antihistamines within 72 hours of Day 1 of the study except as premedication for chemotherapy (e.g., taxanes)
Symptomatic primary or metastatic CNS disease.
Has ongoing vomiting, retching, clinically significant nausea caused by any etiology, or has a history of anticipatory nausea and vomiting.
Has vomited and/or has had dry heaves/retching within 24 hours prior to the start of MECon Day 1 in Cycle 1.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01500226

Contacts

Contact: Rupal Kalapanda, PMP

781.325.1114

Rkalapanda@tesarobio.com

Locations

United States, Massachusetts
TESARO Inc	Recruiting
Waltham, Massachusetts, United States, 02451

Sponsors and Collaborators

Tesaro, Inc.

Investigators

Study Director:

Allen Poma, MD

Tesaro, Inc.

More Information

No publications provided

Responsible Party:	Tesaro, Inc.
ClinicalTrials.gov Identifier:	NCT01500226 History of Changes
Other Study ID Numbers:	TS-P04834
Study First Received:	December 22, 2011
Last Updated:	October 24, 2012
Health Authority:	United States: Food and Drug Administration

Keywords provided by Tesaro, Inc.:

Rolapitant
Nausea
Vomiting
CINV
Chemotherapy

Additional relevant MeSH terms:

Nausea
Vomiting
Signs and Symptoms, Digestive
Signs and Symptoms
Dexamethasone acetate
Dexamethasone
Granisetron
Dexamethasone 21-phosphate
BB 1101
Emetics
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Antiemetics
Autonomic Agents

Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Agents
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents

ClinicalTrials.gov processed this record on May 23, 2013

A Safety and Efficacy Study of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Moderately Emetogenic Chemotherapy (MEC)